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Lhe Third World Symposium on Pulmonary Arterial Hy-
ertension (PAH) created the opportunity to evaluate mul-
iple new findings into the causes and management of this
ife-threatening and devastating disease. Led by task force
embers, the scientific presentations allowed a collective
haring of knowledge and provided a specialized forum by
hich to establish new benchmarks in the pathogenesis,
athophysiology, diagnosis, treatment, and monitoring of
AH.
Although mysteries still surround the trigger factor(s)
nitiating the pathological changes seen in PAH, we now
nderstand more of the mechanisms involved. A genetic
utation of bone morphogenetic protein receptor-2, part of
he transforming-growth-factor-beta superfamily, appears
o have some association with familial and idiopathic PAH.
ith much still unknown, research has allowed us to
onsider that genetic elements may play a fundamental role,
lthough this could cover a broad range of factors such as
ndothelin (ET), prostacyclin (PGI2) synthase, nitric oxide
NO) synthase, the serotonin transporter, and voltage-gated
otassium channels.
Superficially, it may appear that the disease process is driven
y vasoconstriction, but it now appears that pulmonary vascular
roliferation and remodeling are the primary forces of patho-
enesis. Endothelial dysfunction is a key element of the
anifestation of disease pathophysiology, marked by pro-
onged elevation of ET coupled with chronic reductions in NO
nd PGI2. Identification of these processes has allowed the
evelopment of specific pharmacologic targets.
Regardless of the etiology, PAH presents as an extremely
erious disease state that is difficult to identify early owing to
he insidious nature of early-stage symptoms. A heightened
wareness of patients at risk, or of early-stage disease
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ignificant pathophysiological changes. The diagnostic pro-
ess is now more clearly defined, with consensus reached on
n algorithm of various investigative tests and procedures to
xclude other causes and to ensure that an accurate diagnosis
f PAH can be reached.
Advances in medical therapies over the past decade reflect
he inroads made into our understanding of PAH. Co-
dministered with conventional supportive therapy, new
rug classes such as endothelin receptor antagonists and
rostanoids are now offering viable treatment options for
hese patients. A focused session on medical therapy during
he Third World Symposium on PAH has led to an
pdated treatment algorithm to guide treating clinicians on
he best practice options for PAH patients.
The dilemma remains as to whom best to treat these
atients, given that the patient population is spread across a
road range of disciplines, such as respiratory, cardiology,
heumatology, and immunology. The global trend is mov-
ng toward a system of designated centers for PAH care,
ith medical teams including all specialties working in a
hared-care approach to patient management. It is no
oincidence that the collaborative approach to this World
ymposium reflects the cooperation required across spe-
ialty groups in the broader medical community, to ensure
hat best possible care is delivered to this orphan disease
tate. To this end, we appreciate the opportunity to dissem-
nate the proceedings of this symposium by means of this
upplement to the Journal of the American College of Cardi-
logy, and we hope that the readership finds it informative
nd useful.
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